dc.contributor.author |
Saito, Akiko M. |
en_US |
dc.contributor.author |
Kami, Masahiro |
en_US |
dc.contributor.author |
Mori, Shin-Ichiro |
en_US |
dc.contributor.author |
Kanda, Yoshinobu |
en_US |
dc.contributor.author |
Suzuki, Ritsuro |
en_US |
dc.contributor.author |
Mineishi, Shin |
en_US |
dc.contributor.author |
Takami, Akiyoshi |
en_US |
dc.contributor.author |
Taniguchi, Shuichi |
en_US |
dc.contributor.author |
Takemoto, Yoshinobu |
en_US |
dc.contributor.author |
Hara, Masamichi |
en_US |
dc.contributor.author |
Yamaguchi, Masaki |
en_US |
dc.contributor.author |
Hino, Masayuki |
en_US |
dc.contributor.author |
Yoshida, Takashi |
en_US |
dc.contributor.author |
Kim, Sung-Won |
en_US |
dc.contributor.author |
Hori, Akiko |
en_US |
dc.contributor.author |
Ohashi, Yasuo |
en_US |
dc.contributor.author |
Takaue, Yoichi |
en_US |
dc.date.accessioned |
2007-09-20T19:03:25Z |
|
dc.date.available |
2008-11-05T15:05:43Z |
en_US |
dc.date.issued |
2007-10 |
en_US |
dc.identifier.citation |
Saito, Akiko M.; Kami, Masahiro; Mori, Shin-Ichiro; Kanda, Yoshinobu; Suzuki, Ritsuro; Mineishi, Shin; Takami, Akiyoshi; Taniguchi, Shuichi; Takemoto, Yoshinobu; Hara, Masamichi; Yamaguchi, Masaki; Hino, Masayuki; Yoshida, Takashi; Kim, Sung-Won; Hori, Akiko; Ohashi, Yasuo; Takaue, Yoichi (2007)."Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan." American Journal of Hematology 82(10): 873-880. <http://hdl.handle.net/2027.42/56131> |
en_US |
dc.identifier.issn |
0361-8609 |
en_US |
dc.identifier.issn |
1096-8652 |
en_US |
dc.identifier.uri |
http://hdl.handle.net/2027.42/56131 |
|
dc.identifier.uri |
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17570513&dopt=citation |
|
dc.description.abstract |
This prospective trial assessed the safety and efficacy of allogeneic hematopoietic stem cell transplantation from a HLA-matched donor with a reduced-intensity regimen (RIST) consisting of iv fludarabine 30 mg/m 2 for 6 days and oral busulfan 4 mg/kg/day for 2 days in patients older than 50 years with hematological malignancies. Cyclosporine alone or cyclosporine with short-term methotrexate was randomized for graft-versus-host disease prophylaxis. After 30 patients had been enrolled, an interim analysis was performed, and this report focuses on a precise evaluation of the toxicity profile and chimerism kinetics. Sustained engraftment in all patients, no severe regimen-related toxicity (RRT) within 20 days, and no transplant-related mortality through Day 100 were observed. T-cell (CD3+) full-donor (over 90%) chimerism was observed in 22 of the 30 patients, while the remaining eight had mixed-donor chimerism over 77% on Day 90. Thereafter, five subsequently converted to full-donor chimerism without donor lymphocyte infusion by day 120 ( n = 4) or Day 180 ( n = 1). Two showed persistent mixed chimerism without relapse through Day 180. Grade III–IV acute graft-versus-host disease and extensive chronic graft-versus-host disease occurred in 10% and 73%, respectively. With a median follow-up of 1.5 years, overall survival and disease-free survival at 1 year was 83% and 62%, respectively. Seven patients hematologically relapsed overall, and five of them had myelodysplastic syndrome with poor prognostic factors. In older patients, RIST with fludarabine and busulfan was associated with acceptable toxicities and a satisfactory antileukemia effect, regardless of the early chimerism status. Am. J. Hematol. 82:873–880, 2007. © 2007 Wiley-Liss, Inc. |
en_US |
dc.format.extent |
169974 bytes |
|
dc.format.extent |
3118 bytes |
|
dc.format.mimetype |
application/pdf |
|
dc.format.mimetype |
text/plain |
|
dc.publisher |
Wiley Subscription Services, Inc., A Wiley Company |
en_US |
dc.subject.other |
Life and Medical Sciences |
en_US |
dc.subject.other |
Cancer Research, Oncology and Pathology |
en_US |
dc.title |
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan |
en_US |
dc.type |
Article |
en_US |
dc.rights.robots |
IndexNoFollow |
en_US |
dc.subject.hlbsecondlevel |
Molecular, Cellular and Developmental Biology |
en_US |
dc.subject.hlbsecondlevel |
Oncology and Hematology |
en_US |
dc.subject.hlbtoplevel |
Health Sciences |
en_US |
dc.subject.hlbtoplevel |
Science |
en_US |
dc.description.peerreviewed |
Peer Reviewed |
en_US |
dc.contributor.affiliationum |
Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan |
en_US |
dc.contributor.affiliationother |
Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; Department of Biostatistics/Epidemiology and Preventive Health Sciences, School of Health Sciences and Nursing, University of Tokyo, Tokyo, Japan ; Dana-Farber Cancer Institute, 44 Binney Street, SM 275 Boston, MA 02115 |
en_US |
dc.contributor.affiliationother |
Division of Exploratory Research, Institution of Medical Science, The University of Tokyo, Tokyo, Japan |
en_US |
dc.contributor.affiliationother |
Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan |
en_US |
dc.contributor.affiliationother |
Department of Cell Therapy and Transplantation Medicine, University of Tokyo Hospital, Tokyo, Japan |
en_US |
dc.contributor.affiliationother |
Department of HSCT Data Management, Nagoya University School of Medicine, Nagoya, Japan |
en_US |
dc.contributor.affiliationother |
Department of Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Ishikawa, Japan |
en_US |
dc.contributor.affiliationother |
Department of Hematology, Toranomon Hospital, Tokyo, Japan |
en_US |
dc.contributor.affiliationother |
Medical Corporation Kouryokai CPC Clinic, Kagoshima, Japan |
en_US |
dc.contributor.affiliationother |
Division of Hematology, Ehime Prefectural Central Hospital, Ehime, Japan |
en_US |
dc.contributor.affiliationother |
Department of Hematology and Immunology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan |
en_US |
dc.contributor.affiliationother |
Department of Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, Osaka, Japan |
en_US |
dc.contributor.affiliationother |
Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan |
en_US |
dc.contributor.affiliationother |
Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan |
en_US |
dc.contributor.affiliationother |
Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan |
en_US |
dc.contributor.affiliationother |
Department of Biostatistics/Epidemiology and Preventive Health Sciences, School of Health Sciences and Nursing, University of Tokyo, Tokyo, Japan |
en_US |
dc.contributor.affiliationother |
Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan |
en_US |
dc.identifier.pmid |
17570513 |
|
dc.description.bitstreamurl |
http://deepblue.lib.umich.edu/bitstream/2027.42/56131/1/20977_ftp.pdf |
en_US |
dc.identifier.doi |
http://dx.doi.org/10.1002/ajh.20977 |
en_US |
dc.identifier.source |
American Journal of Hematology |
en_US |
dc.owningcollname |
Interdisciplinary and Peer-Reviewed |
|